Product Description
For Umbilical cord-derived allogeneic mesenchymal stem cells in Patients With Pitt Hopkins Syndrome (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05165017)
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Pakistan
Approved Indications: None
Company: The Foundation for Orthopaedics and Regenerative Medicine
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Venous Insufficiency|Vision, Low
Phase 1: Asthma|Chronic Obstructive Pulmonary Disease|Idiopathic Pulmonary Fibrosis|Eye Injuries|Retinal Degeneration|Rett Syndrome|Tourette Syndrome|Optic Nerve Injuries|Optic Atrophy|Diabetic Retinopathy|Optic Nerve Diseases|Macular Degeneration|Retinitis Pigmentosa|Polycystic Ovary Syndrome|Cerebral Palsy|Spinal Cord Injuries|Arthritis, Rheumatoid|Multiple Sclerosis|Kidney Failure, Chronic|Spondylitis|Amyotrophic Lateral Sclerosis|Other|Penile Induration|Osteoarthritis|Inflammatory Bowel Diseases|Oligospermia|Spondylarthritis|Heart Failure|Osteoporosis|Skin Ulcer|Autism Spectrum Disorder|Cystitis, Interstitial|Scleroderma, Diffuse|General Diabetes|Traumatic Brain Injury|Erectile Dysfunction|Arthritis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05018793 |
SC-8-GR-10-02 | P1 |
Recruiting |
Spinal Cord Injuries |
2028-12-01 |
2025-04-18 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05158127 |
ATG-2-MSC-015 | P1 |
Not yet recruiting |
Skin Ulcer |
2028-12-01 |
2025-04-18 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05018832 |
SC-20-ATG-12-4 | P1 |
Not yet recruiting |
Traumatic Brain Injury |
2028-11-01 |
2025-04-18 |
Primary Endpoints |
|
NCT05018858 |
SC-20-ATG-4 | P1 |
Recruiting |
Arthritis |
2028-10-01 |
2025-04-09 |
||
NCT05003921 |
SC-7-ATG-7-01 | P1 |
Suspended |
Amyotrophic Lateral Sclerosis |
2028-09-01 |
2025-04-18 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT05147675 |
ATG-1-MSC-011 | P1 |
Recruiting |
Spondylitis|Osteoarthritis|Spondylarthritis |
2027-12-01 |
2025-06-11 |
Primary Endpoints|Treatments|Trial Status |
|
NCT05003960 |
SC-8-ATG-8-02 | P1 |
Recruiting |
Autism Spectrum Disorder |
2027-12-01 |
2023-09-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT05018767 |
SC-11-ATG-12-01 | P1 |
Recruiting |
Other |
2027-12-01 |
2025-04-05 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT06143527 |
2023MSC-01 | P1 |
Recruiting |
Polycystic Ovary Syndrome |
2027-11-16 |
2023-11-27 |
Primary Endpoints|Treatments |
|
NCT05018819 |
SC-11-ATG-11-02 | P1 |
Recruiting |
Cerebral Palsy |
2027-11-01 |
2025-04-09 |
Primary Endpoints |
|
NCT05016804 |
SC-10-ATG-12-04 | P1 |
Recruiting |
Scleroderma, Diffuse |
2026-11-01 |
2025-04-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT05003934 |
SC-8-ATG-10-03 | P1 |
Recruiting |
Arthritis, Rheumatoid |
2026-09-01 |
2025-04-09 |
Primary Endpoints |
|
NCT05147701 |
ATG-1-MSC-014 | P1 |
Recruiting |
Eye Injuries|Retinitis Pigmentosa|Diabetic Retinopathy|Optic Atrophy|Optic Nerve Diseases|Macular Degeneration|Retinal Degeneration|Optic Nerve Injuries |
2026-01-01 |
2025-04-18 |
Primary Endpoints |
|
NCT05152290 |
ATG-1-MSC-012 | P1 |
Recruiting |
Spinal Cord Injuries |
2026-01-01 |
2022-10-28 |
Primary Endpoints|Start Date|Treatments |
|
NCT05158439 |
ATG-2-MSC-014 | P1 |
Withdrawn |
Tourette Syndrome|Rett Syndrome |
2026-01-01 |
2022-02-12 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
NCT05147779 |
ATG-1-MSC-015 | P1 |
Recruiting |
Erectile Dysfunction|Penile Induration|Cystitis, Interstitial |
2025-12-01 |
2022-10-28 |
Primary Endpoints|Start Date|Treatments |
|
NCT05147688 |
ATG-1-MSC-013 | P1 |
Recruiting |
Chronic Obstructive Pulmonary Disease|Asthma |
2025-12-01 |
2021-12-08 |
Primary Endpoints|Treatments |
|
NCT05018845 |
SC-20-ATG-22 | P1 |
Recruiting |
Kidney Failure, Chronic |
2025-11-01 |
2022-10-28 |
Primary Endpoints|Start Date|Treatments |
|
NCT05016817 |
SC-10-ATG-13-08 | P1 |
Recruiting |
Idiopathic Pulmonary Fibrosis |
2025-11-01 |
2025-04-18 |
||
NCT05003388 |
SC-8-ATG-9-03 | P1 |
Recruiting |
Multiple Sclerosis |
2025-10-01 |
2022-10-28 |
Primary Endpoints|Start Date|Treatments |
|
NCT05003947 |
SC-8-ATG-11-04 | P1 |
Recruiting |
Inflammatory Bowel Diseases |
2025-10-01 |
2022-10-28 |
||
NCT05152381 |
ATG-1-MSC-018 | P1 |
Withdrawn |
Osteoporosis |
2025-04-04 |
2025-04-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT05003908 |
SC-10-ATG-11-01 | P1 |
Terminated |
General Diabetes |
2025-04-04 |
2025-04-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05147766 |
ATG-1-MSC-017 | P1 |
Terminated |
Heart Failure |
2025-04-03 |
2025-04-08 |
Primary Endpoints |
|
NCT05158114 |
ATG-2-MSC-013 | P1 |
Withdrawn |
Oligospermia |
2025-04-03 |
2025-04-08 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |